Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience

G. Lainakis; Flora Zagouri; Efstathios Kastritis; Theodoros Ν. Sergentanis; George Bozas; Meletios A Dimopoulos; Christos Papadimitriou

doi:10.1177/030089161109700105

Abstract

1 min read

Though our data reflect a small sample size, pemetrexed plus cisplatin accomplished a particularly high clinical benefit rate on chemo-naïve patients.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

Αngeliki Andrikopoulou, Oraianthi Fiste, Kleoniki Apostolidou, Efthymia Skafida, Christos Markellos, Michalis Liontos, Anastasios Kyriazoglou, Meletios A Dimopoulos, Flora Zagouri

Article2023

Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma

Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo

Article2008

Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer

Giannis Mountzios, Meletios A Dimopoulos, Christos Papadimitriou

Article2005

Carboplatin Hypersensitivity Reactions: A Single Institution Experience

Markella-P. Zorzou, Eleni Efstathiou, Eleni Galani, George Bozas, Efstathios Kastritis, Christos Papadimitriou, Meletios A Dimopoulos, Aristotle Bamias

Article2006

Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for frontline chemotherapy of advanced ovarian carcinoma (AOC): A Hellenic Cooperative Oncology Group Study

Gerasimos Aravantinos, George Fountzilas, Haralabos P. Kalofonos, D. Skarlos, P. Kosmidis, Irene Grimani, Nicholas Pavlidis, D. Bafaloukos, Dimitrios Pectasides, Meletios A Dimopoulos